Trabedersen is under clinical development by Oncotelic Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Trabedersen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Trabedersen overview

Trabedersen (OT-101) is under development for the treatment of pancreatic adenocarcinoma, myelodysplastic syndrome (MDS), long covid-19, malignant melanoma, high grade glioma, colorectal carcinoma, low-grade gliomas and solid tumor in combination with immunotherapy (NK/IL-2),  malignant pleural mesothelioma  and pediatric diffuse intrinsic pontine glioma. The drug candidate is administered by intravenous, infusion and intratumoral route as a solution. It is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer). It is also under development for pneumonia and coronavirus disease 2019 (COVID-19). It was also under development for lung cancer, renal cell cancer, prostate cancer, refractory anaplastic astrocytoma (AA) and other neoplasms, non-small cell lung cancer, glioblastoma.

Oncotelic Therapeutics overview

Oncotelic Therapeutics (OTI) is a pharmaceutical and healthcare company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting agents. OTI is developing a product for the treatment of anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, ovarian cancer, stage IV follicular thyroid cancer, and others. The company offers development pipelines such as CA4P, OT-101, AL-101, ArtiVeda/ArtiShield, and Oxi4503. It also conducts multiple clinical trials in oncology to discover small-molecule anticancer agents belonging to benzosuberene class of compounds. It operates through researchers at the University of Florida and the University of Arhus on anti-angiogenic and anti-metastatic agents. Oxigene is headquartered in Aguora Hills, California, the US.

For a complete picture of Trabedersen’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.